NEW YORK, Aug. 11 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) today announced results for its fiscal quarter ended June 30, 2008.
For the three months ended June 30, 2008, revenues were $1,141,000, as compared to $826,000 for the three months ended June 30, 2007. The increase was primarily attributable to revenues from a research and testing agreement. Loss from operations for the three months ended June 30, 2008 was $1,278,000, as compared to a loss from operations of $2,809,000 for the three months ended June 30, 2007. Net loss attributable to common stockholders for the three months ended June 30, 2008 was $1,383,000, or $0.09 per share, compared to a loss of $2,796,000, or $0.18 per share, in the previous year.
At June 30, 2008, unrestricted cash and cash equivalents were $3,574,000 as compared to $5,996,000 at March 31, 2008. For the same periods, restricted funds on deposit were $2,001,000 and $3,776,000, respectively.
The Company will hold a conference call on Thursday, August 28, 2008 at 2:00 P.M. (EDT) to present an update on the Company's progress and results for fiscal first quarter 2009 results. The User Access Code is # 60063484. Investors and interested parties in the U.S. are invited to join the call by dialing (888) 338-8374 and callers outside the U.S. should call (706) 902-3163. Please call no later than 10 minutes prior to the scheduled start of the call to register. Information to access a recording of the conference call will be available starting on August 28th from the Immtech Pharmaceuticals web site (http://www.immtechpharma.com).
About Immtech Pharmaceuticals, Inc.
Immtech is a pharmaceutical company
|SOURCE Immtech Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved